R
Reunion Neuroscience
Reunion Neurology specializes in neurological treatment and research
About Reunion Neuroscience
Reunion Neuroscience is an early-stage pharmaceutical company focused on the discovery and development of proprietary drug candidates designed to engage serotonergic receptors in the brain. The company aims to push the boundaries of neuroscience to create safer and more accessible therapeutics for millions of people whose mental health needs are not met by current treatments. Reunion Neuroscience operates in the pharmaceutical and biotechnology market, primarily serving patients suffering from depression and other mental health disorders. The business model involves extensive research and development (R&D) to create novel drug candidates, which are then brought to market through clinical trials and regulatory approval processes. Revenue is generated through the commercialization of these therapeutics, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. The company is dedicated to transforming lives by making mental and emotional wellbeing the baseline for everyone.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2025 | $30M | $515M | Undisclosed | ↗ |
| SERIES AOther financing | May 2024 | $103M | $412M | Mitsui · Palo Santo Venture Fund · Plaisance Capital · MPM BioImpact | ↗ |
Growth signals
Latest recorded traffic for Reunion Neuroscience is 6.3K monthly website visits, up 125% over the last three months. Reunion Neuroscience's team grew 6.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Reunion Neuroscience in the Philadelphia ecosystem
The Reunion Neuroscience office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Novo Holdings
Mitsui
Palo Santo Venture Fund
Plaisance Capital
Arkin Capital
FemHealth Ventures
Series B and later1 investor entered at this stage
MPM BioImpact
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reunion Neuroscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reunion Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










